New president for SentoClone

Rune Bremberg today assumes his post as the President of biotechnology company SentoClone AB. Bremberg has been a member of the Board of SentoClone for some time. Johan Järte, the current President will remain within the company until further notice.

Rune Bremberg has more than 25 years of experience from the global pharmaceuticals industry, including companies such as Rhone-Poulenc Rorer and Pfizer. His most recent position was as Group Vice President at Wyeth Pharmaceuticals.

Since Johan Järte was appointed President of SentoClone in 2007, the company has undergone a dramatic development. Today, more than 100 patients have been treated with SentoClone's therapy, with pilot studies having been conducted on colon cancer, among others. The company is now in a new phase. In the autumn of 2009, a randomised clinical trial commenced on metastasised malignant melanoma. The objective is to commercialise the patented treatment method internationally.

"The results we have so far observed at the individual level are highly interesting and the clinical programme we are now conducting gives me reason to see great future potential," says Rune Bremberg.

In the spring of 2010, the company is planning to release a new share issue.

For further information, please contact:

Ã…ke Plyhm
Chairman of the Board
SentoClone AB
Mobile: +46 (0)705 65 86 31
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Rune Bremberg
President
SentoClone AB
Mobile: +46 (0)705 20 28 95
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Thursday, 11 March 2010 12:39